Patentable/Patents/US-9727691
US-9727691

Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene

PublishedAugust 8, 2017
Assigneenot available in USPTO data we have
Inventorsnot available in USPTO data we have
Technical Abstract

The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.

Patent Claims
10 claims

Legal claims defining the scope of protection. Each claim is shown in both the original legal language and a plain English translation.

Claim 1

Original Legal Text

1. A method for treating a human subject with fentanyl following surgery comprising: (a) obtaining from the human subject a nucleic acid sample; (b) detecting the nucleic acids in the nucleic acid sample to determine the genotype of the rs2952768 polymorphism; (c1) administering to the human subject having a C/C genotype at rs2952768 a higher amount of fentanyl, wherein the higher amount of fentanyl is in comparison to predetermined median reference value, or (c2) administering to the human subject having a T/C or T/T genotype at rs2952768 a lower amount of fentanyl, wherein the lower amount of fentanyl is in comparison to predetermined median reference value.

Plain English Translation

A method for personalized fentanyl dosing after surgery based on genetic information. First, a DNA sample is collected from a patient. The method then analyzes the sample to determine the patient's genotype at the rs2952768 polymorphism. If the patient has a C/C genotype, a higher dose of fentanyl is administered compared to a standard reference value. If the patient has a T/C or T/T genotype, a lower dose of fentanyl is administered compared to the standard reference value.

Claim 2

Original Legal Text

2. The method according to claim 1 , wherein the nucleic acid sample is extracted from blood or oral mucosa of the human subject.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, involves obtaining the DNA sample from either a blood sample or a sample of cells from the oral mucosa (cells from inside the mouth). This sample is then used to determine the genotype at the rs2952768 polymorphism for guiding fentanyl dosage.

Claim 3

Original Legal Text

3. The method according to claim 1 , wherein the surgery is orthognathic surgery, and wherein the predetermined median reference value is 2.268 μg/kg.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing orthognathic surgery (corrective jaw surgery). In this specific case, the standard reference value for fentanyl dosage used for comparison is 2.268 μg/kg. The patient's rs2952768 genotype is still used to determine whether to administer a higher or lower dose relative to this reference.

Claim 4

Original Legal Text

4. The method according to claim 1 , wherein 4.80 to 5.08 μg/kg of fentanyl is administered to the human subject having a C/C genotype at rs2952768 after orthognathic surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing orthognathic surgery (corrective jaw surgery). If a patient has a C/C genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 4.80 and 5.08 μg/kg following the surgery.

Claim 5

Original Legal Text

5. The method according to claim 1 , wherein 2.38 to 2.78 μg/kg of fentanyl is administered to the human subject having a T/T genotype at rs2952768 after orthognathic surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing orthognathic surgery (corrective jaw surgery). If a patient has a T/T genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 2.38 and 2.78 μg/kg following the surgery.

Claim 6

Original Legal Text

6. The method according to claim 1 , wherein 2.38 to 2.99 μg/kg of fentanyl is administered to the human subject having a T/C genotype at rs2952768 after orthognathic surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing orthognathic surgery (corrective jaw surgery). If a patient has a T/C genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 2.38 and 2.99 μg/kg following the surgery.

Claim 7

Original Legal Text

7. The method according to claim 1 , wherein the surgery is abdominal surgery, and wherein the predetermined median reference value is 2.453 μg/kg.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing abdominal surgery. In this specific case, the standard reference value for fentanyl dosage used for comparison is 2.453 μg/kg. The patient's rs2952768 genotype is still used to determine whether to administer a higher or lower dose relative to this reference.

Claim 8

Original Legal Text

8. The method according to claim 1 , wherein 1.12 to 1.78 μg/kg of fentanyl is administered to the human subject having a C/C genotype at rs2952768 after abdominal surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing abdominal surgery. If a patient has a C/C genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 1.12 and 1.78 μg/kg following the surgery.

Claim 9

Original Legal Text

9. The method according to claim 1 , wherein 0.43 to 0.93 μg/kg of fentanyl is administered to the human subject having a T/T genotype at rs2952768 after abdominal surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing abdominal surgery. If a patient has a T/T genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 0.43 and 0.93 μg/kg following the surgery.

Claim 10

Original Legal Text

10. The method according to claim 1 , wherein 0.67 to 0.78 μg/kg of fentanyl is administered to the human subject having a T/C genotype at rs2952768 after abdominal surgery.

Plain English Translation

The method for personalized fentanyl dosing after surgery, as described in claim 1, is specifically applied to patients undergoing abdominal surgery. If a patient has a T/C genotype at the rs2952768 polymorphism, the method involves administering a fentanyl dosage between 0.67 and 0.78 μg/kg following the surgery.

Classification Codes (CPC)

Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.

Patent Metadata

Filing Date

October 1, 2012

Publication Date

August 8, 2017

Want to explore more patents?

Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.

Citation & reuse

Analysis on this page is generated by Patentable — an AI-powered patent intelligence platform. AI-generated summaries, explanations, FAQs, and analysis may be reused with attribution and a visible link back to the canonical URL below. Patent abstracts and claims are USPTO public domain.

Cite as: Patentable. “Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene” (US-9727691). https://patentable.app/patents/US-9727691

© 2026 Nomic Interactive Technology LLC. Machine-readable context available at /api/llm-context/US-9727691. See llms.txt for full attribution policy.